Famewave Ltd.

Ccam Biotherapeutics Ltd.

Biond Biologies Ltd.

Ramot at Tel-aviv University Ltd.

Tel Hashomer Medical Research Infrastructure and Services Ltd.

Ilana Mandel

Yair Sapir

Gal Markel

Tehila Ben-Moshe

Jacob Schachter

Rona Ortenberg

Timothy David Jones

Robert George E Holgate

Francis Joseph Carr

Tehila Ben Moshe

Francis J Carr

Avidor Shulman

Ayala Lewkowicz

Dror Alishekevitz

Dana Haves Ziv

Motti Hakim

Anna Fridman-Dror

Tsuri Peretz

Ilana Goldshtein

Edna Meilin

Robert George Holgate

Lilach Chen Zeltsburg

Rozi Ravit Uzan Gueta

Orit Shilovitzky

Rotem Faygenboim-Ornai

Yossi Gottfried

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Humanized antibodies against CEACAM1

Polynucleotides encoding humanized antibodies against CEACAM1

The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.

Antibodies against ILT2

The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.

Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Growing community of inventors

Carmiel, Israel

Ilana Mandel